Key terms
About TRVN
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TRVN news
Apr 02
6:26am ET
Buy Rating Affirmed on Trevena as Focus Shifts to Promising Drug Candidate TRV045
Apr 01
1:35pm ET
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising TRV045 Development
Apr 01
7:01am ET
Trevena reports Q4 EPS ($1.06) vs (73c) last year
Apr 01
6:12am ET
Trevena Inc Unveils Updated Corporate Strategy Presentation
Mar 11
6:40am ET
Analysts Offer Insights on Healthcare Companies: Trevena (TRVN), MoonLake Immunotherapeutics (MLTX) and Senseonics Holdings (SENS)
Jan 10
4:34pm ET
Trevena files to sell 2.78M shares of common stock for holders
No recent press releases are available for TRVN
TRVN Financials
Key terms
Ad Feedback
TRVN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TRVN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range